105 related articles for article (PubMed ID: 19043710)
1. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.
Kilburn LB; Bonate PL; Blaney SM; McGuffey L; Nuchtern JG; Dauser R; Thompson P; Gibson BW; Berg SL
Cancer Chemother Pharmacol; 2009 Jul; 64(2):335-40. PubMed ID: 19043710
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite.
Bonate PL; Beyerlein D; Crawford J; Roth S; Krumbholz R; Schmid S
AAPS J; 2007 Dec; 9(3):E378-87. PubMed ID: 18170985
[TBL] [Abstract][Full Text] [Related]
3. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
5. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
[TBL] [Abstract][Full Text] [Related]
7. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
[TBL] [Abstract][Full Text] [Related]
8. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
[TBL] [Abstract][Full Text] [Related]
9. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Berg SL; Aleksic A; McGuffey L; Dauser R; Nuchtern J; Bernacky B; Blaney SM
Cancer Chemother Pharmacol; 2004 Aug; 54(2):127-30. PubMed ID: 15150671
[TBL] [Abstract][Full Text] [Related]
11. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
Meany HJ; Fox E; McCully C; Tucker C; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):387-92. PubMed ID: 17932674
[TBL] [Abstract][Full Text] [Related]
12. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
[TBL] [Abstract][Full Text] [Related]
13. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM
Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342
[TBL] [Abstract][Full Text] [Related]
14. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate.
Ray A; Okouneva T; Manna T; Miller HP; Schmid S; Arthaud L; Luduena R; Jordan MA; Wilson L
Cancer Res; 2007 Apr; 67(8):3767-76. PubMed ID: 17440090
[TBL] [Abstract][Full Text] [Related]
16. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.
Berg SL; Bonate PL; Nuchtern JG; Dauser R; McGuffey L; Bernacky B; Blaney SM
Clin Cancer Res; 2005 Aug; 11(16):5981-3. PubMed ID: 16115942
[TBL] [Abstract][Full Text] [Related]
17. Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates.
Serabe BM; Murry DJ; Dauser R; Nuchtern J; Durfee J; McGuffey L; Berg S; Blaney SM
Cancer Chemother Pharmacol; 1999; 43(5):415-8. PubMed ID: 10100598
[TBL] [Abstract][Full Text] [Related]
18. L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys.
Hammerstad JP; Woodward WR; Gliessman P; Boucher B; Nutt JG
Ann Neurol; 1990 May; 27(5):495-9. PubMed ID: 2360790
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
Lopez JA; Beardsley GP; Krikorian JG; Mortara RW; Agarwal RP
Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
[TBL] [Abstract][Full Text] [Related]
20. A primate model for study of methotrexate pharmacokinetics in the central nervous system.
Poplack DG; Bleyer WA; Wood JH; Kostolich M; Savitch JL; Ommaya AK
Cancer Res; 1977 Jul; 37(7 Pt 1):1982-5. PubMed ID: 405092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
